Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, November 13, 2023 Basilea Pharmaceutica Ltd, Allschwil , a commercial-stage biopharmaceutical company committed to meeting...

Related Keywords

Basilea ,Basel Stadt ,Switzerland ,Allschwil ,Switzerland General ,China ,United States ,American ,America ,Swiss ,David Veitch ,Cresemba Zevtera ,Nils Schr ,Drug Administration ,Amplyx Pharmaceuticals Inc ,Swiss Exchange ,Head Of Corporate Communications Investor Relations ,Pfizer ,American Thoracic Society ,Basilea Pharmaceutica International Ltd ,Basilea Pharmaceutica Ltd ,Pfizer Inc ,Pharmaceutica Ltd ,Amplyx Pharmaceuticals ,Chief Executive Officer ,Fast Track ,Orphan Drug ,Qualified Infectious Disease Product ,Corporate Communications ,Pharmaceutica International Ltd ,First In Class Broad Spectrum Agent ,Invasive Fungal ,Oral Fosmanogepix ,First In Class Antifungal Agent ,Antimicrobial Agents ,Novel Antifungal ,Candidemia Caused ,Infectious Disease Clinics ,North America ,Blood Infection ,New England Journal ,Markets ,